Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
ETFs with VRTX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.56%||PowerShares Dynamic Biotech &Genome (PBE)||-1.10 (-2.84%)|
|4.03%||VanEck Vectors Biotech ETF (BBH)||+1.25 (1.22%)|
|3.61%||iShares Nasdaq Biotechnology Index Fund (IBB)||-6.43 (-2.39%)|
|1.51%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+3.56 (6.99%)|
|0.13%||PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (PRFZ)||+12.87 (14.89%)|
Company Description (as filed with the SEC)
We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative drugs for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other indications, while maintaining our financial strength. Cystic Fibrosis Our goal is twofold: to develop treatment regimens that will provide benefits to as many patients with CF as possible and to enhance those benefits. Our two marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. ... More ...
Where does VRTX fit in the risk graph?
|Annual EPS Est:||$-2.07|
|Quarterly EPS Est:||0.05|